# A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

> **NCT03811652** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 8 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Squamous (NSCLC-Sq)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Small Cell Lung Cancer (SCLC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Colorectal Cancer (CRC)
- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** MEDI7247

## Key facts

- **NCT ID:** NCT03811652
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-20
- **Primary completion:** 2019-12-10
- **Final completion:** 2019-12-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811652, "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03811652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*